Natera's Signatera test will be used to select and monitor eligible patients with KRAS-mutant tumors who have molecular residual disease after surgery.
In a survey conducted by an association working group, 40 percent of respondents said they are already offering TMB, with most others planning to do the same within the year.
The company will test a peptide array approach that it believes can identify MSI-high, immunotherapy-responsive individuals more cheaply and easily than existing tests.
